BIORESTORATIVE THERAPIES, INC. Financials BioRestorative Therapies, Inc.
Equities
BRTX
US0906556065
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.25 USD | +1.63% |
|
-8.76% | -28.16% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 0.8251 | 15.16 | 10.1 | 8.19 | 8.462 | - | - |
| Enterprise Value (EV) 1 | 0.8251 | 15.16 | 10.1 | 8.19 | 8.462 | 8.462 | 8.462 |
| P/E ratio | -2,760 x | -0.12 x | -0.54 x | -0.51 x | -0.59 x | -0.59 x | -0.79 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 10.7 x | 330 x | 84.3 x | 56.2 x | 141 x | 141 x | 141 x |
| EV / Revenue | 10.7 x | 330 x | 84.3 x | 56.2 x | 141 x | 141 x | 141 x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 29.9 | 3,493 | 3,674 | 4,707 | 6,770 | - | - |
| Reference price 2 | 27.60 | 4.340 | 2.750 | 1.740 | 1.250 | 1.250 | 1.250 |
| Announcement Date | 4/30/21 | 3/30/22 | 3/27/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.077 | 0.046 | 0.1198 | 0.1458 | 0.06 | 0.06 | 0.06 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -26.31 | -18.97 | -15.22 | -17.81 | -20.73 | -25.18 |
| Operating Margin | - | -57,191.02% | -15,838.09% | -10,439.49% | -29,685.83% | -34,543.33% | -41,964.17% |
| Earnings before Tax (EBT) 1 | - | -44.3 | -18.49 | -14.42 | -17.61 | -20.51 | -24.94 |
| Net income 1 | - | -44.3 | -18.49 | -14.42 | -17.61 | -20.51 | -24.94 |
| Net margin | - | -96,311.52% | -15,438.04% | -9,887.16% | -29,352.5% | -34,176.67% | -41,560.83% |
| EPS 2 | -0.0100 | -37.30 | -5.110 | -3.420 | -2.130 | -2.105 | -1.580 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/30/21 | 3/30/22 | 3/27/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.005 | 0.016 | 0.029 | 0.0037 | 0.0313 | 0.0645 | 0.0307 | 0.0193 | 0.03 | 0.03 | 0.03 | 0.03 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.009 | -5.054 | -4.61 | -4.682 | -5.779 | -3.117 | -3.104 | -3.221 | -3.508 | -3.94 | -4.483 | -5.174 |
| Operating Margin | -80,185.4% | -31,586.19% | -15,895.52% | -126,537.84% | -18,463.58% | -4,831.86% | -10,112.18% | -16,687.46% | -11,693.33% | -13,133.33% | -14,943.33% | -17,246.67% |
| Earnings before Tax (EBT) 1 | - | - | -4.656 | -4.348 | -5.684 | -2.981 | -2.925 | -2.825 | -3.408 | -3.84 | -4.383 | -5.074 |
| Net income 1 | -20.4 | -4.816 | -4.656 | -4.348 | -5.684 | -2.981 | -2.925 | -2.825 | -3.408 | -3.84 | -4.383 | -5.074 |
| Net margin | -408,062.8% | -30,100.94% | -16,054.59% | -117,501.35% | -18,160.45% | -4,621.01% | -9,529.28% | -14,638.45% | -11,360% | -12,800% | -14,610% | -16,913.33% |
| EPS 2 | -6.990 | -1.370 | -1.280 | -1.180 | -1.530 | -0.7700 | -0.6400 | -0.5700 | -0.5100 | -0.4600 | -0.5200 | -0.4800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/22 | 5/16/22 | 11/14/22 | 3/27/23 | 5/12/23 | 8/11/23 | 11/13/23 | 4/1/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 4/30/21 | 3/30/22 | 3/27/23 | 4/1/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.25
USD
Average target price
10.5
USD
Spread / Average Target
+740.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.16% | 8.46M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BRTX Stock
- Financials BioRestorative Therapies, Inc.
